Zhaoke Ophthalmology Limited (HKG:6622)

Hong Kong · Delayed Price · Currency is HKD

2.500

+0.015 (0.60%)

Sep 18, 2026, 3:45 PM HKT

Market Cap	1.37B -34.4%
Revenue (ttm)	40.41M -1.0%
Net Income	-248.16M
EPS	-0.45
Shares Out	548.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	224,000
Open	2.485
Previous Close	2.485
Day's Range	2.470 - 2.515
52-Week Range	2.380 - 3.940
Beta	1.08
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 11, 2026

About Zhaoke Ophthalmology

Zhaoke Ophthalmology Limited operates as an ophthalmic pharmaceutical company in Hong Kong, Mainland China, South Korea, and internationally. The company develops Cyclosporine A ophthalmic gel for the treatment of dry eye disease (DED); RGN-259, an eye drop indicated for moderate-to-severe DED; CsA/rebamipide ophthalmic gel for anti-inflammation and tear film stabilization; and IC-265 in Phase II clinical trial for the treatment of allergic conjunctivitis. It also engages in the development of NVK-002, an ophthalmic solution to control or slow ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2017

Employees 285

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 6622

Full Company Profile

Financial Performance

In 2025, Zhaoke Ophthalmology's revenue was 31.97 million, a decrease of -53.88% compared to the previous year's 69.32 million. Losses were -208.98 million, -12.00% less than in 2024.

Financial numbers in CNY Financial Statements